The effect of budesonide mouthwash on oral chronic graft versus host disease

American Journal of Hematology

Volumn 82, Issue 5, 2007, Pages 349-356

  Sari, Ismail ^a   Altuntas, Fevzi ^a   Kocyigit, Ismail ^a   Sisman, Yildiray ^a   Eser, Bulent ^a   Unal, Aydin ^a   Fen, Turgay ^b   Ferahbas, Ayten ^a   Ozturk, Ahmet ^a   Unal, Ali ^a   Cetin, Mustafa ^a  

^a ERCIYES UNIVERSITY   (Turkey)

^b Ankara Atatiirk Teaching and Research Hospital   (Turkey)

Author keywords

Budesonide; Oral chronic graft versus host disease; Stem cell transplantation

Indexed keywords

BUDESONIDE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; METHOTREXATE; PREDNISONE; SODIUM CHLORIDE; STEROID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DRUG EFFECT; DRUG POTENCY; FEMALE; HEMATOPOIETIC STEM CELL; HODGKIN DISEASE; HUMAN; MALE; MORBIDITY; MOUTHWASH; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; SYSTEMIC DISEASE; SYSTEMIC THERAPY; THRUSH; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; BUDESONIDE; CANDIDIASIS, ORAL; CHRONIC DISEASE; COHORT STUDIES; CYCLOSPORINE; DRUG EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MOUTHWASHES; PAIN MEASUREMENT; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDNISONE; RETROSPECTIVE STUDIES; SODIUM CHLORIDE; STOMATITIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 34247491583     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20814     Document Type: Article

References (41)

1. Sullivan KM. Graft-versus-host-disease. In: Thomas ED, Blume KG, Forman SJ, editors. Hematopoietic Cell Transplantation. Malden, Mass: Blackwell Science; 2004. pp 635-664.
2. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-217.
3. Lee S, Cook EF, Soiffer R, Antin JH. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2002;8:444-452.
4. Akpek G, Lee SJ, Flowers ME, et al. Performance of a new clinical grading system for chronic graft-versus-host disease: A multicenter study. Blood 2003;102:802-809.
5. Woo SB, Lee SJ, Schubert MM. Graft-vs-host disease. Crit Rev Oral Biol Med 1997;8:201-216.
6. Schwinghammer TL, Bloom EJ. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation. Clin Pharm 1993;12:736-761.
7. Horn TD, Rest EB, Mirenski Y, Corio RL, Zahurak ML, Vogelsang GB. The significance of oral mucosal and salivary gland pathology after allogeneic bone marrow transplantation. Arch Dermatol 1995;131:964-965.
8. Nagler RM, Nagler A. Major salivary gland involvement in graft-vs.-host disease: Considerations related to pathogenesis, the role of cytokines and therapy. Cytokines Cell Mol Ther 1999;5:227-232.
9. Iwasaki T. Recent advances in the treatment of graft-versus-host disease. Clin Med Res 2004;2:243-252.
10. Jacobsohn DA, Margolis J, Doherty J, Anders V, Vogelsang GB. Weight loss and malnutrition in patients with chronic graft-vs-host disease. Bone Marrow Transplant 2002;29:231-236.
11. Epstein JB, Gorsky M, Epstein MS, Nantel S. Topical azathioprine in the treatment of immune-mediated chronic oral inflammatory conditions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91:56-61.
12. Epstein JB, Reece DE. Topical cyclosporine A for treatment of oral chronic graft-versus-host disease. Bone Marrow Transplant 1994;13:81-86.
13. Redding SW, Callander NS, Haveman CW, Leonard DL. Treatment of oral chronic graft-versus-host disease with PUVA therapy: Case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86:183-187.
14. Elad S, Garfunkel AA, Enk CD, Galili D, Or R. Ultraviolet B irradiation: A new therapeutic concept for the management of oral manifestations of graft-versus-host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;88:444-450.
15. Brogdan RN, McTravish D. Budesonide. An updated review of its pharmacological properties and therapeutic effects in asthma and rhinitis. Drugs 1992;44:375-407.
16. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842-845.
17. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-956.
18. Pavletic SZ, Martin P, Lee SJ, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006;12:252-266.
19. Sullivan K, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosupression. Blood 1981;57:267-276.
20. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: Long-term follow-up of a randomized trial. Blood 2002;100:415-419.
21. Hogan W, Storb R. Use of cyclosporine in hematopoietic cell transplantation. Transplant Proc 2004;36:367-371.
22. Sullivan K, Witherspoon RP, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 1988;72:555-561.
23. Koc S, Leisenring W, Flowers ME, et al. Therapy for chronic graft-versus-host disease: A randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002;100:48-51.
24. Akpek G, Lee SM, Anders V, Vogelsang GB. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001;7:495-502.
25. Johnston L, Brown J, Shizuru JA, et al. Rapamycin (sirolimus) for treatment of chronic graft versus-host disease. Biol Blood Marrow Transplant 2005;11:47-55.
26. Busca A, Locatelli F, Marmont F, Audisio E, Falda M. Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease. Haematologica 2003;88:837-839.
27. Dall'Amico R, Messina C. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Ther Apher 2002;6:296-304.
28. Gilman A, Chan KW, Mogul A, et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000;6:327-334.
29. Lee S, Wegner SA, McGarigle CJ, Bierer BE, Antin JH. Treatment of chronic graft-versus-host disease with clofazimine. Blood 1997;89:2298-2302.
30. Parker P, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995;86:3604-3609.
31. Goldberg J, Jacobsohn DA, Margolis J, et al. Pentostatin for the treatment of chronic graft-versus-host disease in children. J Pediatr Hematol Oncol 2003;25:584-588.
32. Giaccone L, Martin P, Carpenter P, et al. Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease. Bone Marrow Transplant 2005;36:337-341.
33. Wolff D, Anders V, Corio R, et al. Oral PUVA and topical steroids for treatment of oral manifestations of chronic graft-vs.-host disease. Photodermatol Photoimmunol Photomed 2004;20:184-190.
34. Epstein J, Truelove EL. Topical cyclosporine in a bioadhesive for treatment of oral lichenoid mucosal reactions: An open label clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;82:532-536.
35. Epstein J, Nantel S, Sheoltch SM. Topical azathioprine in the combined treatment of chronic oral graft-versus-host disease. Bone Marrow Transplant 2000;25:683-687.
36. Eckardt A, Starke O, Stadler M, Reuter C, Hertenstein B. Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: Highly effective treatment with topical tacrolimus. Oral Oncol 2004;40:811-814.
37. Spencer CM, McTravish D. Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 1995;50:854-872.
38. Hellers G, Cortot A, Jewell D, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD budesonide study group. Gastroenterology 1999;116:294-300.
39. Lofberg R, Danielsson A, Suhr O, et al. Oral budesonide versus prednisolone in patients with active extensive and left sided ulcerative colitis. Gastroenterology 1996;110:1713-1718.
40. Bertz H, Afting M, Kreisel W, Duffner U, Greinwald R, Finke J. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bone Marrow Transplant 1999;24:1185-1189.
41. Elad S, Or R, Garfunkel AA, Shapira MY. Budesonide: A novel treatment for oral chronic graft versus host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95:308-331.